Global Anti-VEGF Drugs for Angiogenesis-related Disease Supply, Demand and Key Producers, 2024-2030
The global Anti-VEGF Drugs for Angiogenesis-related Disease market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).
Anti-VEGF (vascular endothelial growth factor) drugs are a class of drugs that inhibit vascular endothelial growth factor (VEGF). They are mainly used to treat diseases related to angiogenesis, including tumors, eye diseases, etc.
This report studies the global Anti-VEGF Drugs for Angiogenesis-related Disease production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Anti-VEGF Drugs for Angiogenesis-related Disease, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Anti-VEGF Drugs for Angiogenesis-related Disease that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Anti-VEGF Drugs for Angiogenesis-related Disease total production and demand, 2019-2030, (K Units)
Global Anti-VEGF Drugs for Angiogenesis-related Disease total production value, 2019-2030, (USD Million)
Global Anti-VEGF Drugs for Angiogenesis-related Disease production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Anti-VEGF Drugs for Angiogenesis-related Disease consumption by region & country, CAGR, 2019-2030 & (K Units)
U.S. VS China: Anti-VEGF Drugs for Angiogenesis-related Disease domestic production, consumption, key domestic manufacturers and share
Global Anti-VEGF Drugs for Angiogenesis-related Disease production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K Units)
Global Anti-VEGF Drugs for Angiogenesis-related Disease production by Type, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Anti-VEGF Drugs for Angiogenesis-related Disease production by Application production, value, CAGR, 2019-2030, (USD Million) & (K Units).
This reports profiles key players in the global Anti-VEGF Drugs for Angiogenesis-related Disease market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Bayer, Genentech, Novartis, Coherus BioSciences Inc., Regeneron, Qilu Pharmaceutical Co.,Ltd., Innovent Biologics and Anke Biotechnology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Anti-VEGF Drugs for Angiogenesis-related Disease market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.
Global Anti-VEGF Drugs for Angiogenesis-related Disease Market, By Region:
1. How big is the global Anti-VEGF Drugs for Angiogenesis-related Disease market?
2. What is the demand of the global Anti-VEGF Drugs for Angiogenesis-related Disease market?
3. What is the year over year growth of the global Anti-VEGF Drugs for Angiogenesis-related Disease market?
4. What is the production and production value of the global Anti-VEGF Drugs for Angiogenesis-related Disease market?
5. Who are the key producers in the global Anti-VEGF Drugs for Angiogenesis-related Disease market?
Anti-VEGF (vascular endothelial growth factor) drugs are a class of drugs that inhibit vascular endothelial growth factor (VEGF). They are mainly used to treat diseases related to angiogenesis, including tumors, eye diseases, etc.
This report studies the global Anti-VEGF Drugs for Angiogenesis-related Disease production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Anti-VEGF Drugs for Angiogenesis-related Disease, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Anti-VEGF Drugs for Angiogenesis-related Disease that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Anti-VEGF Drugs for Angiogenesis-related Disease total production and demand, 2019-2030, (K Units)
Global Anti-VEGF Drugs for Angiogenesis-related Disease total production value, 2019-2030, (USD Million)
Global Anti-VEGF Drugs for Angiogenesis-related Disease production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Anti-VEGF Drugs for Angiogenesis-related Disease consumption by region & country, CAGR, 2019-2030 & (K Units)
U.S. VS China: Anti-VEGF Drugs for Angiogenesis-related Disease domestic production, consumption, key domestic manufacturers and share
Global Anti-VEGF Drugs for Angiogenesis-related Disease production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K Units)
Global Anti-VEGF Drugs for Angiogenesis-related Disease production by Type, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Anti-VEGF Drugs for Angiogenesis-related Disease production by Application production, value, CAGR, 2019-2030, (USD Million) & (K Units).
This reports profiles key players in the global Anti-VEGF Drugs for Angiogenesis-related Disease market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Bayer, Genentech, Novartis, Coherus BioSciences Inc., Regeneron, Qilu Pharmaceutical Co.,Ltd., Innovent Biologics and Anke Biotechnology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Anti-VEGF Drugs for Angiogenesis-related Disease market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.
Global Anti-VEGF Drugs for Angiogenesis-related Disease Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Ranibizumab
- Brolucizumab
- Aflibercept
- Conbercept
- Faricimab
- Others
- Tumor
- Eye Diseases
- Others
- Roche
- Bayer
- Genentech
- Novartis
- Coherus BioSciences Inc.
- Regeneron
- Qilu Pharmaceutical Co.,Ltd.
- Innovent Biologics
- Anke Biotechnology
- Shenzhen Kangzhe Pharmaceutical Co Ltd
- Chengdu Kanghong Pharmaceutical Group
- Rongchang Biology
- Youzhiyou Bio
1. How big is the global Anti-VEGF Drugs for Angiogenesis-related Disease market?
2. What is the demand of the global Anti-VEGF Drugs for Angiogenesis-related Disease market?
3. What is the year over year growth of the global Anti-VEGF Drugs for Angiogenesis-related Disease market?
4. What is the production and production value of the global Anti-VEGF Drugs for Angiogenesis-related Disease market?
5. Who are the key producers in the global Anti-VEGF Drugs for Angiogenesis-related Disease market?
1 SUPPLY SUMMARY
1.1 Anti-VEGF Drugs for Angiogenesis-related Disease Introduction
1.2 World Anti-VEGF Drugs for Angiogenesis-related Disease Supply & Forecast
1.2.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value (2019 & 2023 & 2030)
1.2.2 World Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030)
1.2.3 World Anti-VEGF Drugs for Angiogenesis-related Disease Pricing Trends (2019-2030)
1.3 World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Region (Based on Production Site)
1.3.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Region (2019-2030)
1.3.2 World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Region (2019-2030)
1.3.3 World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Region (2019-2030)
1.3.4 North America Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030)
1.3.5 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030)
1.3.6 China Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030)
1.3.7 Japan Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030)
1.4 Market Drivers, Restraints and Trends
1.4.1 Anti-VEGF Drugs for Angiogenesis-related Disease Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Anti-VEGF Drugs for Angiogenesis-related Disease Major Market Trends
2 DEMAND SUMMARY
2.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Demand (2019-2030)
2.2 World Anti-VEGF Drugs for Angiogenesis-related Disease Consumption by Region
2.2.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Consumption by Region (2019-2024)
2.2.2 World Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Forecast by Region (2025-2030)
2.3 United States Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030)
2.4 China Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030)
2.5 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030)
2.6 Japan Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030)
2.7 South Korea Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030)
2.8 ASEAN Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030)
2.9 India Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030)
3 WORLD ANTI-VEGF DRUGS FOR ANGIOGENESIS-RELATED DISEASE MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Manufacturer (2019-2024)
3.2 World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Manufacturer (2019-2024)
3.3 World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Manufacturer (2019-2024)
3.4 Anti-VEGF Drugs for Angiogenesis-related Disease Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Anti-VEGF Drugs for Angiogenesis-related Disease in 2023
3.5.3 Global Concentration Ratios (CR8) for Anti-VEGF Drugs for Angiogenesis-related Disease in 2023
3.6 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Overall Company Footprint Analysis
3.6.1 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Region Footprint
3.6.2 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Type Footprint
3.6.3 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Comparison
4.1.1 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Comparison (2019 & 2023 & 2030)
4.1.2 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share Comparison (2019 & 2023 & 2030)
4.2 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Production Comparison
4.2.1 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Production Comparison (2019 & 2023 & 2030)
4.2.2 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share Comparison (2019 & 2023 & 2030)
4.3 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Comparison
4.3.1 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Comparison (2019 & 2023 & 2030)
4.3.2 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Market Share Comparison (2019 & 2023 & 2030)
4.4 United States Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers and Market Share, 2019-2024
4.4.1 United States Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value (2019-2024)
4.4.3 United States Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2024)
4.5 China Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers and Market Share
4.5.1 China Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value (2019-2024)
4.5.3 China Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2024)
4.6 Rest of World Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers and Market Share, 2019-2024
4.6.1 Rest of World Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value (2019-2024)
4.6.3 Rest of World Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2024)
5 MARKET ANALYSIS BY TYPE
5.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Market Size Overview by Type: 2019 VS 2023 VS 2030
5.2 Segment Introduction by Type
5.2.1 Ranibizumab
5.2.2 Brolucizumab
5.2.3 Aflibercept
5.2.4 Conbercept
5.2.5 Faricimab
5.2.6 Others
5.3 Market Segment by Type
5.3.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Type (2019-2030)
5.3.2 World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Type (2019-2030)
5.3.3 World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2019-2030)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Market Size Overview by Application: 2019 VS 2023 VS 2030
6.2 Segment Introduction by Application
6.2.1 Tumor
6.2.2 Eye Diseases
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Application (2019-2030)
6.3.2 World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Application (2019-2030)
6.3.3 World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2019-2030)
7 COMPANY PROFILES
7.1 Roche
7.1.1 Roche Details
7.1.2 Roche Major Business
7.1.3 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.1.4 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.1.5 Roche Recent Developments/Updates
7.1.6 Roche Competitive Strengths & Weaknesses
7.2 Bayer
7.2.1 Bayer Details
7.2.2 Bayer Major Business
7.2.3 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.2.4 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.2.5 Bayer Recent Developments/Updates
7.2.6 Bayer Competitive Strengths & Weaknesses
7.3 Genentech
7.3.1 Genentech Details
7.3.2 Genentech Major Business
7.3.3 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.3.4 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.3.5 Genentech Recent Developments/Updates
7.3.6 Genentech Competitive Strengths & Weaknesses
7.4 Novartis
7.4.1 Novartis Details
7.4.2 Novartis Major Business
7.4.3 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.4.4 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.4.5 Novartis Recent Developments/Updates
7.4.6 Novartis Competitive Strengths & Weaknesses
7.5 Coherus BioSciences Inc.
7.5.1 Coherus BioSciences Inc. Details
7.5.2 Coherus BioSciences Inc. Major Business
7.5.3 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.5.4 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.5.5 Coherus BioSciences Inc. Recent Developments/Updates
7.5.6 Coherus BioSciences Inc. Competitive Strengths & Weaknesses
7.6 Regeneron
7.6.1 Regeneron Details
7.6.2 Regeneron Major Business
7.6.3 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.6.4 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.6.5 Regeneron Recent Developments/Updates
7.6.6 Regeneron Competitive Strengths & Weaknesses
7.7 Qilu Pharmaceutical Co.,Ltd.
7.7.1 Qilu Pharmaceutical Co.,Ltd. Details
7.7.2 Qilu Pharmaceutical Co.,Ltd. Major Business
7.7.3 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.7.4 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.7.5 Qilu Pharmaceutical Co.,Ltd. Recent Developments/Updates
7.7.6 Qilu Pharmaceutical Co.,Ltd. Competitive Strengths & Weaknesses
7.8 Innovent Biologics
7.8.1 Innovent Biologics Details
7.8.2 Innovent Biologics Major Business
7.8.3 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.8.4 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.8.5 Innovent Biologics Recent Developments/Updates
7.8.6 Innovent Biologics Competitive Strengths & Weaknesses
7.9 Anke Biotechnology
7.9.1 Anke Biotechnology Details
7.9.2 Anke Biotechnology Major Business
7.9.3 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.9.4 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.9.5 Anke Biotechnology Recent Developments/Updates
7.9.6 Anke Biotechnology Competitive Strengths & Weaknesses
7.10 Shenzhen Kangzhe Pharmaceutical Co Ltd
7.10.1 Shenzhen Kangzhe Pharmaceutical Co Ltd Details
7.10.2 Shenzhen Kangzhe Pharmaceutical Co Ltd Major Business
7.10.3 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.10.4 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.10.5 Shenzhen Kangzhe Pharmaceutical Co Ltd Recent Developments/Updates
7.10.6 Shenzhen Kangzhe Pharmaceutical Co Ltd Competitive Strengths & Weaknesses
7.11 Chengdu Kanghong Pharmaceutical Group
7.11.1 Chengdu Kanghong Pharmaceutical Group Details
7.11.2 Chengdu Kanghong Pharmaceutical Group Major Business
7.11.3 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.11.4 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.11.5 Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
7.11.6 Chengdu Kanghong Pharmaceutical Group Competitive Strengths & Weaknesses
7.12 Rongchang Biology
7.12.1 Rongchang Biology Details
7.12.2 Rongchang Biology Major Business
7.12.3 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.12.4 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.12.5 Rongchang Biology Recent Developments/Updates
7.12.6 Rongchang Biology Competitive Strengths & Weaknesses
7.13 Youzhiyou Bio
7.13.1 Youzhiyou Bio Details
7.13.2 Youzhiyou Bio Major Business
7.13.3 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.13.4 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.13.5 Youzhiyou Bio Recent Developments/Updates
7.13.6 Youzhiyou Bio Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Anti-VEGF Drugs for Angiogenesis-related Disease Industry Chain
8.2 Anti-VEGF Drugs for Angiogenesis-related Disease Upstream Analysis
8.2.1 Anti-VEGF Drugs for Angiogenesis-related Disease Core Raw Materials
8.2.2 Main Manufacturers of Anti-VEGF Drugs for Angiogenesis-related Disease Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Anti-VEGF Drugs for Angiogenesis-related Disease Production Mode
8.6 Anti-VEGF Drugs for Angiogenesis-related Disease Procurement Model
8.7 Anti-VEGF Drugs for Angiogenesis-related Disease Industry Sales Model and Sales Channels
8.7.1 Anti-VEGF Drugs for Angiogenesis-related Disease Sales Model
8.7.2 Anti-VEGF Drugs for Angiogenesis-related Disease Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Anti-VEGF Drugs for Angiogenesis-related Disease Introduction
1.2 World Anti-VEGF Drugs for Angiogenesis-related Disease Supply & Forecast
1.2.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value (2019 & 2023 & 2030)
1.2.2 World Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030)
1.2.3 World Anti-VEGF Drugs for Angiogenesis-related Disease Pricing Trends (2019-2030)
1.3 World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Region (Based on Production Site)
1.3.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Region (2019-2030)
1.3.2 World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Region (2019-2030)
1.3.3 World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Region (2019-2030)
1.3.4 North America Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030)
1.3.5 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030)
1.3.6 China Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030)
1.3.7 Japan Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030)
1.4 Market Drivers, Restraints and Trends
1.4.1 Anti-VEGF Drugs for Angiogenesis-related Disease Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Anti-VEGF Drugs for Angiogenesis-related Disease Major Market Trends
2 DEMAND SUMMARY
2.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Demand (2019-2030)
2.2 World Anti-VEGF Drugs for Angiogenesis-related Disease Consumption by Region
2.2.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Consumption by Region (2019-2024)
2.2.2 World Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Forecast by Region (2025-2030)
2.3 United States Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030)
2.4 China Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030)
2.5 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030)
2.6 Japan Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030)
2.7 South Korea Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030)
2.8 ASEAN Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030)
2.9 India Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030)
3 WORLD ANTI-VEGF DRUGS FOR ANGIOGENESIS-RELATED DISEASE MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Manufacturer (2019-2024)
3.2 World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Manufacturer (2019-2024)
3.3 World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Manufacturer (2019-2024)
3.4 Anti-VEGF Drugs for Angiogenesis-related Disease Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Anti-VEGF Drugs for Angiogenesis-related Disease in 2023
3.5.3 Global Concentration Ratios (CR8) for Anti-VEGF Drugs for Angiogenesis-related Disease in 2023
3.6 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Overall Company Footprint Analysis
3.6.1 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Region Footprint
3.6.2 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Type Footprint
3.6.3 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Comparison
4.1.1 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Comparison (2019 & 2023 & 2030)
4.1.2 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share Comparison (2019 & 2023 & 2030)
4.2 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Production Comparison
4.2.1 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Production Comparison (2019 & 2023 & 2030)
4.2.2 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share Comparison (2019 & 2023 & 2030)
4.3 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Comparison
4.3.1 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Comparison (2019 & 2023 & 2030)
4.3.2 United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Market Share Comparison (2019 & 2023 & 2030)
4.4 United States Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers and Market Share, 2019-2024
4.4.1 United States Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value (2019-2024)
4.4.3 United States Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2024)
4.5 China Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers and Market Share
4.5.1 China Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value (2019-2024)
4.5.3 China Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2024)
4.6 Rest of World Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers and Market Share, 2019-2024
4.6.1 Rest of World Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value (2019-2024)
4.6.3 Rest of World Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2024)
5 MARKET ANALYSIS BY TYPE
5.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Market Size Overview by Type: 2019 VS 2023 VS 2030
5.2 Segment Introduction by Type
5.2.1 Ranibizumab
5.2.2 Brolucizumab
5.2.3 Aflibercept
5.2.4 Conbercept
5.2.5 Faricimab
5.2.6 Others
5.3 Market Segment by Type
5.3.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Type (2019-2030)
5.3.2 World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Type (2019-2030)
5.3.3 World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2019-2030)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Market Size Overview by Application: 2019 VS 2023 VS 2030
6.2 Segment Introduction by Application
6.2.1 Tumor
6.2.2 Eye Diseases
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Application (2019-2030)
6.3.2 World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Application (2019-2030)
6.3.3 World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2019-2030)
7 COMPANY PROFILES
7.1 Roche
7.1.1 Roche Details
7.1.2 Roche Major Business
7.1.3 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.1.4 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.1.5 Roche Recent Developments/Updates
7.1.6 Roche Competitive Strengths & Weaknesses
7.2 Bayer
7.2.1 Bayer Details
7.2.2 Bayer Major Business
7.2.3 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.2.4 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.2.5 Bayer Recent Developments/Updates
7.2.6 Bayer Competitive Strengths & Weaknesses
7.3 Genentech
7.3.1 Genentech Details
7.3.2 Genentech Major Business
7.3.3 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.3.4 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.3.5 Genentech Recent Developments/Updates
7.3.6 Genentech Competitive Strengths & Weaknesses
7.4 Novartis
7.4.1 Novartis Details
7.4.2 Novartis Major Business
7.4.3 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.4.4 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.4.5 Novartis Recent Developments/Updates
7.4.6 Novartis Competitive Strengths & Weaknesses
7.5 Coherus BioSciences Inc.
7.5.1 Coherus BioSciences Inc. Details
7.5.2 Coherus BioSciences Inc. Major Business
7.5.3 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.5.4 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.5.5 Coherus BioSciences Inc. Recent Developments/Updates
7.5.6 Coherus BioSciences Inc. Competitive Strengths & Weaknesses
7.6 Regeneron
7.6.1 Regeneron Details
7.6.2 Regeneron Major Business
7.6.3 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.6.4 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.6.5 Regeneron Recent Developments/Updates
7.6.6 Regeneron Competitive Strengths & Weaknesses
7.7 Qilu Pharmaceutical Co.,Ltd.
7.7.1 Qilu Pharmaceutical Co.,Ltd. Details
7.7.2 Qilu Pharmaceutical Co.,Ltd. Major Business
7.7.3 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.7.4 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.7.5 Qilu Pharmaceutical Co.,Ltd. Recent Developments/Updates
7.7.6 Qilu Pharmaceutical Co.,Ltd. Competitive Strengths & Weaknesses
7.8 Innovent Biologics
7.8.1 Innovent Biologics Details
7.8.2 Innovent Biologics Major Business
7.8.3 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.8.4 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.8.5 Innovent Biologics Recent Developments/Updates
7.8.6 Innovent Biologics Competitive Strengths & Weaknesses
7.9 Anke Biotechnology
7.9.1 Anke Biotechnology Details
7.9.2 Anke Biotechnology Major Business
7.9.3 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.9.4 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.9.5 Anke Biotechnology Recent Developments/Updates
7.9.6 Anke Biotechnology Competitive Strengths & Weaknesses
7.10 Shenzhen Kangzhe Pharmaceutical Co Ltd
7.10.1 Shenzhen Kangzhe Pharmaceutical Co Ltd Details
7.10.2 Shenzhen Kangzhe Pharmaceutical Co Ltd Major Business
7.10.3 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.10.4 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.10.5 Shenzhen Kangzhe Pharmaceutical Co Ltd Recent Developments/Updates
7.10.6 Shenzhen Kangzhe Pharmaceutical Co Ltd Competitive Strengths & Weaknesses
7.11 Chengdu Kanghong Pharmaceutical Group
7.11.1 Chengdu Kanghong Pharmaceutical Group Details
7.11.2 Chengdu Kanghong Pharmaceutical Group Major Business
7.11.3 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.11.4 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.11.5 Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
7.11.6 Chengdu Kanghong Pharmaceutical Group Competitive Strengths & Weaknesses
7.12 Rongchang Biology
7.12.1 Rongchang Biology Details
7.12.2 Rongchang Biology Major Business
7.12.3 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.12.4 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.12.5 Rongchang Biology Recent Developments/Updates
7.12.6 Rongchang Biology Competitive Strengths & Weaknesses
7.13 Youzhiyou Bio
7.13.1 Youzhiyou Bio Details
7.13.2 Youzhiyou Bio Major Business
7.13.3 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
7.13.4 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.13.5 Youzhiyou Bio Recent Developments/Updates
7.13.6 Youzhiyou Bio Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Anti-VEGF Drugs for Angiogenesis-related Disease Industry Chain
8.2 Anti-VEGF Drugs for Angiogenesis-related Disease Upstream Analysis
8.2.1 Anti-VEGF Drugs for Angiogenesis-related Disease Core Raw Materials
8.2.2 Main Manufacturers of Anti-VEGF Drugs for Angiogenesis-related Disease Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Anti-VEGF Drugs for Angiogenesis-related Disease Production Mode
8.6 Anti-VEGF Drugs for Angiogenesis-related Disease Procurement Model
8.7 Anti-VEGF Drugs for Angiogenesis-related Disease Industry Sales Model and Sales Channels
8.7.1 Anti-VEGF Drugs for Angiogenesis-related Disease Sales Model
8.7.2 Anti-VEGF Drugs for Angiogenesis-related Disease Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Region (2019, 2023 and 2030) & (USD Million)
Table 2. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Region (2019-2024) & (USD Million)
Table 3. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Region (2025-2030) & (USD Million)
Table 4. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share by Region (2019-2024)
Table 5. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share by Region (2025-2030)
Table 6. World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Region (2019-2024) & (K Units)
Table 7. World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Region (2025-2030) & (K Units)
Table 8. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share by Region (2019-2024)
Table 9. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share by Region (2025-2030)
Table 10. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Region (2019-2024) & (US$/Unit)
Table 11. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Region (2025-2030) & (US$/Unit)
Table 12. Anti-VEGF Drugs for Angiogenesis-related Disease Major Market Trends
Table 13. World Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Growth Rate Forecast by Region (2019 & 2023 & 2030) & (K Units)
Table 14. World Anti-VEGF Drugs for Angiogenesis-related Disease Consumption by Region (2019-2024) & (K Units)
Table 15. World Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Forecast by Region (2025-2030) & (K Units)
Table 16. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Manufacturer (2019-2024) & (USD Million)
Table 17. Production Value Market Share of Key Anti-VEGF Drugs for Angiogenesis-related Disease Producers in 2023
Table 18. World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Manufacturer (2019-2024) & (K Units)
Table 19. Production Market Share of Key Anti-VEGF Drugs for Angiogenesis-related Disease Producers in 2023
Table 20. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Manufacturer (2019-2024) & (US$/Unit)
Table 21. Global Anti-VEGF Drugs for Angiogenesis-related Disease Company Evaluation Quadrant
Table 22. World Anti-VEGF Drugs for Angiogenesis-related Disease Industry Rank of Major Manufacturers, Based on Production Value in 2023
Table 23. Head Office and Anti-VEGF Drugs for Angiogenesis-related Disease Production Site of Key Manufacturer
Table 24. Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Type Footprint
Table 25. Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Application Footprint
Table 26. Anti-VEGF Drugs for Angiogenesis-related Disease Competitive Factors
Table 27. Anti-VEGF Drugs for Angiogenesis-related Disease New Entrant and Capacity Expansion Plans
Table 28. Anti-VEGF Drugs for Angiogenesis-related Disease Mergers & Acquisitions Activity
Table 29. United States VS China Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Comparison, (2019 & 2023 & 2030) & (USD Million)
Table 30. United States VS China Anti-VEGF Drugs for Angiogenesis-related Disease Production Comparison, (2019 & 2023 & 2030) & (K Units)
Table 31. United States VS China Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Comparison, (2019 & 2023 & 2030) & (K Units)
Table 32. United States Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value, (2019-2024) & (USD Million)
Table 34. United States Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share (2019-2024)
Table 35. United States Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2024) & (K Units)
Table 36. United States Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share (2019-2024)
Table 37. China Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value, (2019-2024) & (USD Million)
Table 39. China Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share (2019-2024)
Table 40. China Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2024) & (K Units)
Table 41. China Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share (2019-2024)
Table 42. Rest of World Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value, (2019-2024) & (USD Million)
Table 44. Rest of World Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share (2019-2024)
Table 45. Rest of World Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2024) & (K Units)
Table 46. Rest of World Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share (2019-2024)
Table 47. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Type, (USD Million), 2019 & 2023 & 2030
Table 48. World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Type (2019-2024) & (K Units)
Table 49. World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Type (2025-2030) & (K Units)
Table 50. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Type (2019-2024) & (USD Million)
Table 51. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Type (2025-2030) & (USD Million)
Table 52. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2019-2024) & (US$/Unit)
Table 53. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2025-2030) & (US$/Unit)
Table 54. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Application, (USD Million), 2019 & 2023 & 2030
Table 55. World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Application (2019-2024) & (K Units)
Table 56. World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Application (2025-2030) & (K Units)
Table 57. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Application (2019-2024) & (USD Million)
Table 58. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Application (2025-2030) & (USD Million)
Table 59. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2019-2024) & (US$/Unit)
Table 60. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2025-2030) & (US$/Unit)
Table 61. Roche Basic Information, Manufacturing Base and Competitors
Table 62. Roche Major Business
Table 63. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 64. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 65. Roche Recent Developments/Updates
Table 66. Roche Competitive Strengths & Weaknesses
Table 67. Bayer Basic Information, Manufacturing Base and Competitors
Table 68. Bayer Major Business
Table 69. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 70. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 71. Bayer Recent Developments/Updates
Table 72. Bayer Competitive Strengths & Weaknesses
Table 73. Genentech Basic Information, Manufacturing Base and Competitors
Table 74. Genentech Major Business
Table 75. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 76. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 77. Genentech Recent Developments/Updates
Table 78. Genentech Competitive Strengths & Weaknesses
Table 79. Novartis Basic Information, Manufacturing Base and Competitors
Table 80. Novartis Major Business
Table 81. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 82. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 83. Novartis Recent Developments/Updates
Table 84. Novartis Competitive Strengths & Weaknesses
Table 85. Coherus BioSciences Inc. Basic Information, Manufacturing Base and Competitors
Table 86. Coherus BioSciences Inc. Major Business
Table 87. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 88. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 89. Coherus BioSciences Inc. Recent Developments/Updates
Table 90. Coherus BioSciences Inc. Competitive Strengths & Weaknesses
Table 91. Regeneron Basic Information, Manufacturing Base and Competitors
Table 92. Regeneron Major Business
Table 93. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 94. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 95. Regeneron Recent Developments/Updates
Table 96. Regeneron Competitive Strengths & Weaknesses
Table 97. Qilu Pharmaceutical Co.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 98. Qilu Pharmaceutical Co.,Ltd. Major Business
Table 99. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 100. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 101. Qilu Pharmaceutical Co.,Ltd. Recent Developments/Updates
Table 102. Qilu Pharmaceutical Co.,Ltd. Competitive Strengths & Weaknesses
Table 103. Innovent Biologics Basic Information, Manufacturing Base and Competitors
Table 104. Innovent Biologics Major Business
Table 105. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 106. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 107. Innovent Biologics Recent Developments/Updates
Table 108. Innovent Biologics Competitive Strengths & Weaknesses
Table 109. Anke Biotechnology Basic Information, Manufacturing Base and Competitors
Table 110. Anke Biotechnology Major Business
Table 111. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 112. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 113. Anke Biotechnology Recent Developments/Updates
Table 114. Anke Biotechnology Competitive Strengths & Weaknesses
Table 115. Shenzhen Kangzhe Pharmaceutical Co Ltd Basic Information, Manufacturing Base and Competitors
Table 116. Shenzhen Kangzhe Pharmaceutical Co Ltd Major Business
Table 117. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 118. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 119. Shenzhen Kangzhe Pharmaceutical Co Ltd Recent Developments/Updates
Table 120. Shenzhen Kangzhe Pharmaceutical Co Ltd Competitive Strengths & Weaknesses
Table 121. Chengdu Kanghong Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 122. Chengdu Kanghong Pharmaceutical Group Major Business
Table 123. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 124. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 125. Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
Table 126. Chengdu Kanghong Pharmaceutical Group Competitive Strengths & Weaknesses
Table 127. Rongchang Biology Basic Information, Manufacturing Base and Competitors
Table 128. Rongchang Biology Major Business
Table 129. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 130. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 131. Rongchang Biology Recent Developments/Updates
Table 132. Youzhiyou Bio Basic Information, Manufacturing Base and Competitors
Table 133. Youzhiyou Bio Major Business
Table 134. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 135. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 136. Global Key Players of Anti-VEGF Drugs for Angiogenesis-related Disease Upstream (Raw Materials)
Table 137. Anti-VEGF Drugs for Angiogenesis-related Disease Typical Customers
Table 138. Anti-VEGF Drugs for Angiogenesis-related Disease Typical Distributors
LIST OF FIGURE
Figure 1. Anti-VEGF Drugs for Angiogenesis-related Disease Picture
Figure 2. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value: 2019 & 2023 & 2030, (USD Million)
Figure 3. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value and Forecast (2019-2030) & (USD Million)
Figure 4. World Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030) & (K Units)
Figure 5. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price (2019-2030) & (US$/Unit)
Figure 6. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share by Region (2019-2030)
Figure 7. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share by Region (2019-2030)
Figure 8. North America Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030) & (K Units)
Figure 9. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030) & (K Units)
Figure 10. China Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030) & (K Units)
Figure 11. Japan Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030) & (K Units)
Figure 12. Anti-VEGF Drugs for Angiogenesis-related Disease Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030) & (K Units)
Figure 15. World Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Market Share by Region (2019-2030)
Figure 16. United States Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030) & (K Units)
Figure 17. China Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030) & (K Units)
Figure 18. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030) & (K Units)
Figure 19. Japan Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030) & (K Units)
Figure 20. South Korea Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030) & (K Units)
Figure 21. ASEAN Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030) & (K Units)
Figure 22. India Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030) & (K Units)
Figure 23. Producer Shipments of Anti-VEGF Drugs for Angiogenesis-related Disease by Manufacturer Revenue ($MM) and Market Share (%): 2023
Figure 24. Global Four-firm Concentration Ratios (CR4) for Anti-VEGF Drugs for Angiogenesis-related Disease Markets in 2023
Figure 25. Global Four-firm Concentration Ratios (CR8) for Anti-VEGF Drugs for Angiogenesis-related Disease Markets in 2023
Figure 26. United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share Comparison (2019 & 2023 & 2030)
Figure 27. United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share Comparison (2019 & 2023 & 2030)
Figure 28. United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Market Share Comparison (2019 & 2023 & 2030)
Figure 29. United States Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share 2023
Figure 30. China Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share 2023
Figure 31. Rest of World Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share 2023
Figure 32. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 33. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share by Type in 2023
Figure 34. Ranibizumab
Figure 35. Brolucizumab
Figure 36. Aflibercept
Figure 37. Conbercept
Figure 38. Faricimab
Figure 39. Others
Figure 40. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share by Type (2019-2030)
Figure 41. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share by Type (2019-2030)
Figure 42. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2019-2030) & (US$/Unit)
Figure 43. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 44. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share by Application in 2023
Figure 45. Tumor
Figure 46. Eye Diseases
Figure 47. Others
Figure 48. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share by Application (2019-2030)
Figure 49. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share by Application (2019-2030)
Figure 50. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2019-2030) & (US$/Unit)
Figure 51. Anti-VEGF Drugs for Angiogenesis-related Disease Industry Chain
Figure 52. Anti-VEGF Drugs for Angiogenesis-related Disease Procurement Model
Figure 53. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Model
Figure 54. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Channels, Direct Sales, and Distribution
Figure 55. Methodology
Figure 56. Research Process and Data Source
Table 1. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Region (2019, 2023 and 2030) & (USD Million)
Table 2. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Region (2019-2024) & (USD Million)
Table 3. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Region (2025-2030) & (USD Million)
Table 4. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share by Region (2019-2024)
Table 5. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share by Region (2025-2030)
Table 6. World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Region (2019-2024) & (K Units)
Table 7. World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Region (2025-2030) & (K Units)
Table 8. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share by Region (2019-2024)
Table 9. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share by Region (2025-2030)
Table 10. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Region (2019-2024) & (US$/Unit)
Table 11. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Region (2025-2030) & (US$/Unit)
Table 12. Anti-VEGF Drugs for Angiogenesis-related Disease Major Market Trends
Table 13. World Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Growth Rate Forecast by Region (2019 & 2023 & 2030) & (K Units)
Table 14. World Anti-VEGF Drugs for Angiogenesis-related Disease Consumption by Region (2019-2024) & (K Units)
Table 15. World Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Forecast by Region (2025-2030) & (K Units)
Table 16. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Manufacturer (2019-2024) & (USD Million)
Table 17. Production Value Market Share of Key Anti-VEGF Drugs for Angiogenesis-related Disease Producers in 2023
Table 18. World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Manufacturer (2019-2024) & (K Units)
Table 19. Production Market Share of Key Anti-VEGF Drugs for Angiogenesis-related Disease Producers in 2023
Table 20. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Manufacturer (2019-2024) & (US$/Unit)
Table 21. Global Anti-VEGF Drugs for Angiogenesis-related Disease Company Evaluation Quadrant
Table 22. World Anti-VEGF Drugs for Angiogenesis-related Disease Industry Rank of Major Manufacturers, Based on Production Value in 2023
Table 23. Head Office and Anti-VEGF Drugs for Angiogenesis-related Disease Production Site of Key Manufacturer
Table 24. Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Type Footprint
Table 25. Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Application Footprint
Table 26. Anti-VEGF Drugs for Angiogenesis-related Disease Competitive Factors
Table 27. Anti-VEGF Drugs for Angiogenesis-related Disease New Entrant and Capacity Expansion Plans
Table 28. Anti-VEGF Drugs for Angiogenesis-related Disease Mergers & Acquisitions Activity
Table 29. United States VS China Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Comparison, (2019 & 2023 & 2030) & (USD Million)
Table 30. United States VS China Anti-VEGF Drugs for Angiogenesis-related Disease Production Comparison, (2019 & 2023 & 2030) & (K Units)
Table 31. United States VS China Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Comparison, (2019 & 2023 & 2030) & (K Units)
Table 32. United States Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value, (2019-2024) & (USD Million)
Table 34. United States Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share (2019-2024)
Table 35. United States Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2024) & (K Units)
Table 36. United States Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share (2019-2024)
Table 37. China Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value, (2019-2024) & (USD Million)
Table 39. China Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share (2019-2024)
Table 40. China Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2024) & (K Units)
Table 41. China Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share (2019-2024)
Table 42. Rest of World Based Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value, (2019-2024) & (USD Million)
Table 44. Rest of World Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share (2019-2024)
Table 45. Rest of World Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2024) & (K Units)
Table 46. Rest of World Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share (2019-2024)
Table 47. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Type, (USD Million), 2019 & 2023 & 2030
Table 48. World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Type (2019-2024) & (K Units)
Table 49. World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Type (2025-2030) & (K Units)
Table 50. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Type (2019-2024) & (USD Million)
Table 51. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Type (2025-2030) & (USD Million)
Table 52. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2019-2024) & (US$/Unit)
Table 53. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2025-2030) & (US$/Unit)
Table 54. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Application, (USD Million), 2019 & 2023 & 2030
Table 55. World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Application (2019-2024) & (K Units)
Table 56. World Anti-VEGF Drugs for Angiogenesis-related Disease Production by Application (2025-2030) & (K Units)
Table 57. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Application (2019-2024) & (USD Million)
Table 58. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Application (2025-2030) & (USD Million)
Table 59. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2019-2024) & (US$/Unit)
Table 60. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2025-2030) & (US$/Unit)
Table 61. Roche Basic Information, Manufacturing Base and Competitors
Table 62. Roche Major Business
Table 63. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 64. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 65. Roche Recent Developments/Updates
Table 66. Roche Competitive Strengths & Weaknesses
Table 67. Bayer Basic Information, Manufacturing Base and Competitors
Table 68. Bayer Major Business
Table 69. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 70. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 71. Bayer Recent Developments/Updates
Table 72. Bayer Competitive Strengths & Weaknesses
Table 73. Genentech Basic Information, Manufacturing Base and Competitors
Table 74. Genentech Major Business
Table 75. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 76. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 77. Genentech Recent Developments/Updates
Table 78. Genentech Competitive Strengths & Weaknesses
Table 79. Novartis Basic Information, Manufacturing Base and Competitors
Table 80. Novartis Major Business
Table 81. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 82. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 83. Novartis Recent Developments/Updates
Table 84. Novartis Competitive Strengths & Weaknesses
Table 85. Coherus BioSciences Inc. Basic Information, Manufacturing Base and Competitors
Table 86. Coherus BioSciences Inc. Major Business
Table 87. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 88. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 89. Coherus BioSciences Inc. Recent Developments/Updates
Table 90. Coherus BioSciences Inc. Competitive Strengths & Weaknesses
Table 91. Regeneron Basic Information, Manufacturing Base and Competitors
Table 92. Regeneron Major Business
Table 93. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 94. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 95. Regeneron Recent Developments/Updates
Table 96. Regeneron Competitive Strengths & Weaknesses
Table 97. Qilu Pharmaceutical Co.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 98. Qilu Pharmaceutical Co.,Ltd. Major Business
Table 99. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 100. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 101. Qilu Pharmaceutical Co.,Ltd. Recent Developments/Updates
Table 102. Qilu Pharmaceutical Co.,Ltd. Competitive Strengths & Weaknesses
Table 103. Innovent Biologics Basic Information, Manufacturing Base and Competitors
Table 104. Innovent Biologics Major Business
Table 105. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 106. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 107. Innovent Biologics Recent Developments/Updates
Table 108. Innovent Biologics Competitive Strengths & Weaknesses
Table 109. Anke Biotechnology Basic Information, Manufacturing Base and Competitors
Table 110. Anke Biotechnology Major Business
Table 111. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 112. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 113. Anke Biotechnology Recent Developments/Updates
Table 114. Anke Biotechnology Competitive Strengths & Weaknesses
Table 115. Shenzhen Kangzhe Pharmaceutical Co Ltd Basic Information, Manufacturing Base and Competitors
Table 116. Shenzhen Kangzhe Pharmaceutical Co Ltd Major Business
Table 117. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 118. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 119. Shenzhen Kangzhe Pharmaceutical Co Ltd Recent Developments/Updates
Table 120. Shenzhen Kangzhe Pharmaceutical Co Ltd Competitive Strengths & Weaknesses
Table 121. Chengdu Kanghong Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 122. Chengdu Kanghong Pharmaceutical Group Major Business
Table 123. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 124. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 125. Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
Table 126. Chengdu Kanghong Pharmaceutical Group Competitive Strengths & Weaknesses
Table 127. Rongchang Biology Basic Information, Manufacturing Base and Competitors
Table 128. Rongchang Biology Major Business
Table 129. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 130. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 131. Rongchang Biology Recent Developments/Updates
Table 132. Youzhiyou Bio Basic Information, Manufacturing Base and Competitors
Table 133. Youzhiyou Bio Major Business
Table 134. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 135. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 136. Global Key Players of Anti-VEGF Drugs for Angiogenesis-related Disease Upstream (Raw Materials)
Table 137. Anti-VEGF Drugs for Angiogenesis-related Disease Typical Customers
Table 138. Anti-VEGF Drugs for Angiogenesis-related Disease Typical Distributors
LIST OF FIGURE
Figure 1. Anti-VEGF Drugs for Angiogenesis-related Disease Picture
Figure 2. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value: 2019 & 2023 & 2030, (USD Million)
Figure 3. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value and Forecast (2019-2030) & (USD Million)
Figure 4. World Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030) & (K Units)
Figure 5. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price (2019-2030) & (US$/Unit)
Figure 6. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share by Region (2019-2030)
Figure 7. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share by Region (2019-2030)
Figure 8. North America Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030) & (K Units)
Figure 9. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030) & (K Units)
Figure 10. China Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030) & (K Units)
Figure 11. Japan Anti-VEGF Drugs for Angiogenesis-related Disease Production (2019-2030) & (K Units)
Figure 12. Anti-VEGF Drugs for Angiogenesis-related Disease Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030) & (K Units)
Figure 15. World Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Market Share by Region (2019-2030)
Figure 16. United States Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030) & (K Units)
Figure 17. China Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030) & (K Units)
Figure 18. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030) & (K Units)
Figure 19. Japan Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030) & (K Units)
Figure 20. South Korea Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030) & (K Units)
Figure 21. ASEAN Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030) & (K Units)
Figure 22. India Anti-VEGF Drugs for Angiogenesis-related Disease Consumption (2019-2030) & (K Units)
Figure 23. Producer Shipments of Anti-VEGF Drugs for Angiogenesis-related Disease by Manufacturer Revenue ($MM) and Market Share (%): 2023
Figure 24. Global Four-firm Concentration Ratios (CR4) for Anti-VEGF Drugs for Angiogenesis-related Disease Markets in 2023
Figure 25. Global Four-firm Concentration Ratios (CR8) for Anti-VEGF Drugs for Angiogenesis-related Disease Markets in 2023
Figure 26. United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share Comparison (2019 & 2023 & 2030)
Figure 27. United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share Comparison (2019 & 2023 & 2030)
Figure 28. United States VS China: Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Market Share Comparison (2019 & 2023 & 2030)
Figure 29. United States Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share 2023
Figure 30. China Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share 2023
Figure 31. Rest of World Based Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share 2023
Figure 32. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 33. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share by Type in 2023
Figure 34. Ranibizumab
Figure 35. Brolucizumab
Figure 36. Aflibercept
Figure 37. Conbercept
Figure 38. Faricimab
Figure 39. Others
Figure 40. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share by Type (2019-2030)
Figure 41. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share by Type (2019-2030)
Figure 42. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2019-2030) & (US$/Unit)
Figure 43. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 44. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share by Application in 2023
Figure 45. Tumor
Figure 46. Eye Diseases
Figure 47. Others
Figure 48. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Market Share by Application (2019-2030)
Figure 49. World Anti-VEGF Drugs for Angiogenesis-related Disease Production Value Market Share by Application (2019-2030)
Figure 50. World Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2019-2030) & (US$/Unit)
Figure 51. Anti-VEGF Drugs for Angiogenesis-related Disease Industry Chain
Figure 52. Anti-VEGF Drugs for Angiogenesis-related Disease Procurement Model
Figure 53. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Model
Figure 54. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Channels, Direct Sales, and Distribution
Figure 55. Methodology
Figure 56. Research Process and Data Source
